ZEN INVESTING
IBM Releases Quantum-HPC Integration Blueprint Targeting Drug Discovery
IBM publishes reference architecture for embedding quantum processors into existing supercomputing centers, enabling molecular simulations beyond classical capabilities.
NVIDIA Survey Shows 70% of Healthcare Firms Now Deploy AI as ROI Hits Mainstream
NVIDIA's 2026 healthcare AI survey reveals adoption jumped to 70% from 63%, with 85% of executives reporting revenue gains and nearly half planning 10%+ budget increases.
Lilly Unveils Groundbreaking AI Factory for Drug Discovery with NVIDIA's DGX SuperPOD
Lilly has launched the largest AI factory in the pharmaceutical sector, leveraging NVIDIA's DGX SuperPOD to revolutionize drug discovery and personalized medicine.
NVIDIA Unveils Biomedical AI-Q Blueprint for Enhanced Drug Discovery
NVIDIA introduces the Biomedical AI-Q Research Agent Blueprint, streamlining drug discovery by expediting literature review and hypothesis generation through AI-driven solutions.
NVIDIA and Novo Nordisk Collaborate to Enhance Drug Discovery with AI
NVIDIA partners with Novo Nordisk and DCAI to leverage AI technology in advancing drug discovery, utilizing the Gefion supercomputer for innovative pharmaceutical research.
AI and Organoids Revolutionize Brain Disease Research
BrainStorm Therapeutics leverages AI and organoids to advance drug discovery for brain diseases, aiming to reduce clinical trial failures and accelerate treatment development.
Protai Leverages NVIDIA NIM and AlphaFold for Enhanced Protein Structure Prediction
Protai advances drug discovery by integrating NVIDIA NIM with AlphaFold and proteomics, optimizing protein structure predictions for precision medicine.
GenMol: A New Frontier in Molecular Generation for Drug Discovery
Explore GenMol, a generalist foundation model for molecular generation, and its advantages over SAFE-GPT in the realm of AI-driven drug discovery.
NVIDIA Introduces BioNeMo Blueprint to Revolutionize Protein Binder Design
NVIDIA unveils the BioNeMo Blueprint, a new AI-powered approach to accelerate protein binder design in drug discovery, leveraging GPU-accelerated microservices.
Mitsui & Co's Xeureka Utilizes NVIDIA AI for Secure Drug Discovery
Xeureka, a subsidiary of Mitsui & Co, leverages NVIDIA's AI platform to safely share healthcare data, enhancing drug discovery efforts through advanced confidential computing.